Trump administration halts global supply of HIV, malaria, tuberculosis drugs
In various memos circulated to the United States Agency for International Development (USAID), the Trump administration has demanded contractors and partners to immediately stop work in supplying lifesaving drugs for HIV, malaria, and tuberculosis to countries supported by the agency.
USAID and its contractors fund programs across the globe that help millions of individuals in the fight against diseases such as HIV/AIDS, malaria, and tuberculosis, particularly in low-income nations. In 2023, the US provided USD$72 billion in aid around the world, and 42% of all global humanitarian aid. The funds provide assistance in clean water access and overall healthcare infrastructure. US Consulting firm Chemonics received one such memo, demanding the firm’s work in providing medical aid and contraception and maternal health supplies to stop.
Former head of global health at USAID Atul Gawande commented, “This is catastrophic. Donated drug supplies keeping 20 million people living with HIV alive – that stops today.” Not only will millions of individuals be prevented from receiving life-saving treatments, Gawande also warned against potential transmission and emergence of drug-resistant strains of viruses like HIV. Other partners of USAID have also received notices to halt work, many of whom are now unable to deliver medicines to clinic despite being in stock, or even open clinics that are funded by the US.
Just hours taking office on January 20, 2025, Trump ordered a 90-day pause on foreign aid to review policy priorities, putting between 57–60 senior career individuals on leave at USAID. This foreign aid includes work encompassing 6.5 million orphans and vulnerable children living with HIV in 23 countries, and the career officials affected include those working in water security, children’s education, and digital technology transformation.
In an interview with The Guardian, former USAID China policy lead Francisco Bencosme stated “This decision undermines our national security and emboldens our adversaries. Instead of focusing on China, North Korea, or Russia, the Trump administration is going after public servants who have served multiple administrations – including the first Trump administration.”
President of Refugees International and former USAID official Jeremy Konyndyk also commented that “If this is not reversed, it will wreck US foreign aid…it would permanently weaken USAID.”
Sources
1. Trumper order set to halt supply of HIV, malaria drugs to poor countries, sources say [Accessed January 29, 2025] https://www.reuters.com/business/healthcare-pharmaceuticals/trump-order-set-halt-supply-hiv-malaria-drugs-poor-countries-sources-say-2025-01-28/
2. Trump administration puts about 60 USAid officials on leave after aid freeze [Accessed January 29, 2025] https://www.theguardian.com/us-news/2025/jan/27/trump-usaid-workers-on-leave-aid-freeze
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...